Chemotherapy in the Older Patient with Operable Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens

Thoracic Surgery Clinics

Volumn 19, Issue 3, 2009, Pages 377-389

  Browner, Ilene ^a   Purtell, Michael ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Elderly; Neoadjuvant chemotherapy; Non small cell lung cancer; Operable

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; UFT; VINBLASTINE; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PNEUMONECTOMY; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 70449107344     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2009.07.005     Document Type: Review

References (88)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 58 2 (2008) 71-96
2. Nesbitt J.C., Putnam Jr. J.B., Walsh G.L., et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60 2 (1995) 466-472
3. Ou S.H., Zell J.A., Ziogas A., et al. Prognostic factors for survival of stage I non-small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California cancer registry from 1989 to 2003. Cancer 110 7 (2007) 1532-1541
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non -small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ 311 7010 (1995) 899-909
5. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26 21 (2008) 3552-3559
6. Berghmans T., Paesmans M., Meert A.P., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 1 (2005) 13-23
7. Aging statistics. Available at:. http://www.aoa.gov/AoARoot/Aging_Statistics/index.aspx Accessed June 13, 2009
8. Rocha Lima C.M., Herndon II J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the cancer and leukemia group B. Cancer 94 1 (2002) 181-187
9. Spaggiari L., and Scanagatta P. Surgery of non-small cell lung cancer in the elderly. Curr Opin Oncol 19 2 (2007) 84-91
10. PACE participants, Audisio R.A., Pope D., et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 65 2 (2008) 156-163
11. Belani C.P. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 32 2 Suppl 2 (2005) S9-S15
12. Brahmer J.R., and Ettinger D.S. Non-small cell lung cancer: adjuvant and neoadjuvant chemotherapy. Respirology 12 3 (2007) 320-325
13. Burdett S., Stewart L.A., and Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1 7 (2006) 611-621
14. Vora N., and Reckamp K.L. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 35 6 (2008) 590-596
15. Peake M.D., Thompson S., Lowe D., et al. Ageism in the management of lung cancer. Age Ageing 32 2 (2003) 171-177
16. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25 35 (2007) 5570-5577
17. Smith T.J., Penberthy L., Desch C.E., et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 13 3 (1995) 235-252
18. Oxnard G.R., Fidias P., Muzikansky A., et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol 2 11 (2007) 1029-1035
19. Hurria A., and Kris M.G. Management of lung cancer in older adults. CA Cancer J Clin 53 6 (2003) 325-341
20. Extermann M., and Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 14 (2007) 1824-1831
21. Rodin M.B., and Mohile S.G. A practical approach to geriatric assessment in oncology. J Clin Oncol 25 14 (2007) 1936-1944
22. Hurria A. Incorporation of geriatric principles in oncology clinical trials. J Clin Oncol 25 34 (2007) 5350-5351
23. Hurria A., Lichtman S.M., Gardes J., et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 55 10 (2007) 1604-1608
24. Klepin H., Mohile S., and Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw 7 2 (2009) 226-236
25. Geriatric oncology: ASCO cancer portals. Available at:. http://geriatricsca.asco.org/CancerPortals/Geriatric+Oncology Accessed June 13, 2009
26. Geriatric assessment tools. Available at:. http://www.siog.org/index.php?option=com_content&view=article&id =103&Itemid=78 Accessed June 13, 2009
27. NCCN clinical practice guidelines in oncology: senior adult oncology. Available at:. http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf Accessed June 13, 2009
28. Cudennec T., Gendry T., Labrune S., et al. Use of a simplified geriatric evaluation in thoracic oncology. Lung Cancer 64 Suppl 1 (2009) S72-S73
29. Girre V., Falcou M.C., Gisselbrecht M., et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?. J Gerontol A Biol Sci Med Sci 63 7 (2008) 724-730
30. Detterbeck F.C., Socinski M.A., Gralla R.J., et al. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. J Thorac Oncol 3 1 (2008) 37-45
31. Alam N., Darling G., Evans W.K., et al. Lung cancer disease site group of cancer care ontario's program in evidence-based care. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 58 2 (2006) 146-155
32. D'Angelillo R.M., Trodella L., and Ramella S. Assessing the value of neoadjuvant chemoradiotherapy and pathologic downstaging in the treatment of non-small cell lung cancer. J Thorac Cardiovasc Surg 128 3 (2004) 489-490
33. Betticher D.C., Hsu Schmitz S.F., Totsch M., et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94 8 (2006) 1099-1106
34. Fruh M., Rolland E., Pignon J.P., et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. J Clin Oncol 26 21 (2008) 3573-3581
35. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup study JBR.10. J Clin Oncol 25 12 (2007) 1553-1561
36. Pisters K.M., Ginsberg R.J., Giroux D.J., et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119 3 (2000) 429-439
37. Pisters K., Vallieres E., Bunn P., et al. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC). Preliminary results. [abstract]. J Clin Oncol 23 16 (2005) LBA7012 Accessed June 13, 2009
38. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330 3 (1994) 153-158
39. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86 9 (1994) 673-680
40. Felip E., Rosell R., Massuti B., et al. The NATCH trial: observations on the neoadjuvant arm. [abstract]. J Clin Oncol 25 18 (2007) 7578
41. Gilligan D., Nicolson M., Smith I., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 369 9577 (2007) 1929-1937
42. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 20 1 (2002) 247-253
43. Rosell R., Felip E., Maestre J., et al. The role of chemotherapy in early non-small cell lung cancer management. Lung Cancer 34 Suppl 3 (2001) S63-S74
44. Garrido P., Gonzalez-Larriba J.L., Insa A., et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small cell lung cancer patients: the Spanish Lung Cancer Group trial 9901. J Clin Oncol 25 30 (2007) 4736-4742
45. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8 2 Suppl (2001) 27-28 [quiz: 1-25]
46. Gridelli C., Langer C., Maione P., et al. Lung cancer in the elderly. J Clin Oncol 25 14 (2007) 1898-1907
47. Gridelli C., Maione P., Comunale D., et al. Adjuvant chemotherapy in elderly patients with non-small cell lung cancer. Cancer Control 14 1 (2007) 57-62
48. Gridelli C., Maione P., Rossi A., et al. Treatment of locally advanced non-small cell lung cancer in the elderly. Curr Opin Oncol 17 2 (2005) 130-134
49. Thyss A., Saudes L., Otto J., et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12 10 (1994) 2121-2125
50. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 3 (2002) 173-181
51. Kubota K., Furuse K., Kawahara M., et al. Cisplatin-based combination chemotherapy for elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 40 6 (1997) 469-474
52. Frasci G., and Southern Italy Cooperative Oncology Group (SICOG). Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 41 3 (2002) 349-361
53. Martini N., Kris M.G., Flehinger B.J., et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55 6 (1993) 1373-1374 [discussion: 1365-73]
54. Takeda S., Maeda H., Okada T., et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg 30 1 (2006) 184-189
55. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374 (2009) 379-386
56. Herth F.J., Annema J.T., Eberhardt R., et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 26 20 (2008) 3346-3350
57. Eschmann S.M., Friedel G., Paulsen F., et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55 2 (2007) 165-171
58. De Leyn P., Stroobants S., De Wever W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small cell lung cancer: a leuven lung cancer group study. J Clin Oncol 24 21 (2006) 3333-3339
59. Dooms C., and Vansteenkiste J. Positron emission tomography in non-small cell lung cancer. Curr Opin Pulm Med 13 4 (2007) 256-260
60. Tanvetyanon T., Eikman E.A., Sommers E., et al. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small cell lung cancer. J Clin Oncol 26 28 (2008) 4610-4616
61. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88 17 (1996) 1210-1215
62. Sause W., Kolesar P., Taylor S.I.V., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 2 (2000) 358-364
63. Langer CJ, Hsu C., Curran W., et al. Do elderly patients with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys 51 3 (2001) 20-21
64. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 21 17 (2003) 3201-3206
65. Vokes E.E., Herndon II J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: cancer and leukemia group B. J Clin Oncol 25 13 (2007) 1698-1704
66. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 25 (2005) 5883-5891
67. Solomon B., and Bunn Jr. P.A. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 25 4 (2007) 217-225
68. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 17 (2004) 1713-1721
69. Hamada C., Tanaka F., Ohta M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. J Clin Oncol 23 22 (2005) 4999-5006
70. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 9 (2006) 719-727
71. Strauss G.M., Herndon JE II, Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the cancer and leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol 26 31 (2008) 5043-5051
72. Scagliotti G.V. The ALPI trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Clin Cancer Res 11 13 Pt 2 (2005) 5011s-5016s
73. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg 26 1 (2004) 173-182
74. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med 352 25 (2005) 2589-2597
75. Le Chevalier T., Dunant A., Arriagada R., et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). [abstract]. J Clin Oncol 26 15 (2008) 7507
76. Besse B., and Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: a fading effect?. J Clin Oncol 26 31 (2008) 5014-5017
77. Roselli M., Mariotti S., Ferroni P., et al. Postsurgical chemotherapy in stage IB non-small cell lung cancer: long-term survival in a randomized study. Int J Cancer 119 4 (2006) 955-960
78. Lee D. Benefit of active treatment in non-small cell lung cancer in elderly patients and patients with poor performance status. Clin Lung Cancer 5 2 (2003) 86-89
79. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 4 (1998) 1582-1587
80. Janssen-Heijnen M.L., Smulders S., Lemmens V.E., et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59 7 (2004) 602-607
81. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25 14 (2007) 1832-1843
82. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991
83. Zheng Z., Chen T., Li X., et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 8 (2007) 800-808
84. Yang C.H., Yu C.J., Shih J.Y., et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26 16 (2008) 2745-2753
85. Richardson F, Richardson K, Sennello D. Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 27: 15s. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_vi ew&confID=60&abstractID=50126. Accessed July 10, 2009.
86. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26 21 (2008) 3543-3551
87. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
88. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 26 1 (2008) 60-65